Polysaccharide Drug Complex for TLR7/8 Solubility and Toxicity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
TLR7/8 agonists like Telratolimod have poor water solubility and cause excessive cytokine release and bone marrow toxicity, preventing their systemic administration.
Innovation Solution
A complex comprising a modified polysaccharide with a hydrophobic group, such as cholesterol-modified pullulan, encapsulating the TLR7/8 agonist Telratolimod, forms gel particles that enhance solubility and reduce toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TLR7/8 agonists with long hydrocarbon chains (e.g., Telratolimod) are administered systemically, then macrophage polarization from M2-like to M1-like is achieved, but excessive cytokine release and bone marrow toxicity occur
Solution Approach 1:
The patent introduces a modified polysaccharide as an intermediary carrier that binds to the TLR7/8 agonist. This carrier acts as a mediator between the drug and the body, improving water solubility while controlling the release kinetics to suppress excessive cytokine release and bone marrow toxicity, thereby enabling safe systemic administration.
Solution Approach 2:
The patent modifies the physical and chemical parameters of the TLR7/8 agonist by conjugating it to a modified polysaccharide. This changes the molecular weight, solubility, and pharmacokinetic parameters of the compound, transforming it from a poorly soluble, toxic agent into a safe, systemically administrable formulation.
2Reliability
If TLR7/8 agonists with long hydrocarbon chains are used, then immunosuppressive activity is enhanced, but water solubility becomes poor
Solution Approach 1:
The patent creates a composite material by conjugating the hydrophobic TLR7/8 agonist with a hydrophilic modified polysaccharide. This composite structure combines the immunosuppressive activity of the original compound with the water solubility of the polysaccharide carrier, resolving the solubility issue while preserving biological activity.
Solution Approach 2:
The modified polysaccharide serves as an intermediary that bridges the hydrophobic drug and the aqueous physiological environment. It maintains the drug's biological activity while providing water solubility through its hydrophilic carbohydrate structure.
3Productivity
If systemic administration of TLR7/8 agonists is attempted, then cancer treatment efficacy is improved, but bone marrow toxicity increases
Solution Approach 1:
The modified polysaccharide carrier acts as a protective intermediary that controls the pharmacokinetics of the TLR7/8 agonist. It prevents direct toxic interaction with bone marrow cells while still enabling sufficient drug exposure to achieve cancer treatment efficacy through controlled release and improved bioavailability.
Solution Approach 2:
The patent applies beforehand cushioning by using the modified polysaccharide carrier to pre-establish a safe delivery platform that mitigates toxic effects before they can occur. The carrier structure is designed to buffer the harmful effects of the compound against sensitive tissues like bone marrow while maintaining therapeutic activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The complex enables systemic administration of TLR7/8 agonists while suppressing excessive cytokine release and bone marrow toxicity, facilitating macrophage polarization from M2-like to M1-like, enhancing cancer treatment efficacy.
Implementation Method 1
a complex comprising a modified polysaccharide containing a hydrophobic group, and a compound represented by formula (1)
Implementation Method 2
the complex according to any one of Items 1 to 10, which is gel particles
Data Source
AI summary
An object is to provide a technique that improves the poor solubility of a compound of formula (1) in water and further suppresses the cytokine excessive release action and bone marrow toxicity of the compound of formula (1). This object is achieved by a complex comprising a modified polysaccharide containing a hydrophobic group, and a compound represented by formula (1).